Develops antibiotics for multidrug-resistant bacterial infections, focusing on addressing unmet medical needs in infectious diseases.
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of treatments targeting multi-drug resistant (MDR) bacterial infections and rare diseases across the United States. Central to its portfolio are innovative product candidates such as tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic aimed at treating complicated urinary tract infections, including pyelonephritis in adults. Additionally, SPR206, an intravenous agent, is being developed to combat MDR Gram-negative bacterial infections within hospital settings, while SPR720 focuses on addressing non-tuberculous mycobacterial pulmonary disease through oral administration.
The company has forged strategic alliances to bolster its development efforts. Spero Therapeutics has entered into a license agreement with Meiji Seika Pharma Co., Ltd. to support the advancement of tebipenem HBr. Furthermore, a collaboration with Everest Medicines enhances its presence in Greater China, South Korea, and Southeast Asian countries for the development, manufacturing, and commercialization of SPR206. Moreover, partnerships with the Bill & Melinda Gates Medical Research Institute and Vertex Pharmaceuticals Incorporated underscore its commitment to advancing treatments like SPR720 and its active metabolite, SPR719, for combating lung infections caused by Mycobacterium tuberculosis.
Established in 2013 and headquartered in Cambridge, Massachusetts, Spero Therapeutics, Inc. continues to pioneer breakthrough therapies addressing critical medical needs through its robust pipeline and strategic partnerships in the biopharmaceutical industry.